<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4248">
  <stage>Registered</stage>
  <submitdate>17/04/2013</submitdate>
  <approvaldate>17/04/2013</approvaldate>
  <nctid>NCT01839149</nctid>
  <trial_identification>
    <studytitle>TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine</studytitle>
    <scientifictitle>A Phase 2, Enriched-enrollment, Randomized-withdrawal, Double-blinded, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Intranasal Oxytocin in Subjects With Chronic Migraine</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TRIG-05</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>High Frequency Episodic Migraine and Chronic Migraine</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - TI-001
Treatment: drugs - Placebo

Experimental: TI-001 (intranasal oxytocin) - TI-001 is intranasal oxytocin

Placebo Comparator: Placebo - Placebo for TI-001 is the same intranasal formulation without oxytocin


Treatment: drugs: TI-001
TI-001 is intranasal oxytocin

Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean change of migraine days - Baseline is the 28-day screening period before study drug administration</outcome>
      <timepoint>Baseline and 28 days of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change of moderate or severe headache days</outcome>
      <timepoint>Baseline and 28 days of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects experiencing a =50% reduction in migraine days</outcome>
      <timepoint>Baseline and 28 days of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in days using rescue medication</outcome>
      <timepoint>Baseline and 28 days of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects experiencing a reduction in headache severity and pain score 2 hours after dosing</outcome>
      <timepoint>Baseline and 28 days of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Men and women, aged 18 to 65 years with primary diagnosis of high frequency episodic
        migraine or chronic migraine.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Known allergy to oxytocin

          2. History of addictive behavior (eg, alcoholism, drug abuse) or severe mood disorder

          3. History of clinically significant, functionally impairing cardiovascular or pulmonary
             disease or any other disease that might confound study results

          4. Have basilar or hemiplegic migraines

          5. Have substantial cognitive or memory impairment due to any cause (eg, Alzheimer's or
             dementia)

          6. Have a nasal obstruction due to any cause

          7. Are pregnant or breast feeding

          8. Require ongoing use of steroidal or nonsteroidal anti-inflammatory drugs

          9. Are unable or unwilling to provide informed consent or to follow study procedures</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>240</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Fitzroy</hospital>
    <hospital> - Prahran</hospital>
    <hospital> - Sherwood</hospital>
    <postcode> - Fitzroy</postcode>
    <postcode> - Prahran</postcode>
    <postcode> - Sherwood</postcode>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Trigemina, Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study evaluates the use of oxytocin, given as a nasal spray, for treatment of high
      frequency episodic migraine and chronic migraine.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01839149</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Raquel Izumi, PhD</name>
      <address>Trigemina, Inc</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>